Elastrin key facts
as of Oct 2026- Developer of biotech therapeutics designed to improve health by restoring damaged hardened tissue to healthy resilience.
- Elastrin is valued at approximately $32.0M as of Oct 2026 (last reported valuation).
- It has raised $20.2M; the latest was Later Stage VC ($500K) in Mar 2025.
- Notable investors include SC Launch, Starbloom Capital, Kizoo Technology Capital, Lung, National Heart — 6 tracked in total.
- Status: Privately Held (backing).
Elastrin's last reported valuation, Nov 2023. Nothing priced has surfaced since.
- ·Watch Elastrin: the Monday email on marks, rounds and moves
Elastrin funding rounds
No funding rounds for Elastrin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Elastrin valuation
Elastrin's last reported valuation was $32 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.
Elastrin investors
6 investors are on record for Elastrin, including SC Launch, Starbloom Capital, Kizoo Technology Capital and Lung.
About Elastrin
Developer of biotech therapeutics designed to improve health by restoring damaged hardened tissue to healthy resilience. The company's therapeutics are focused on developing novel therapies by reversing the hardening of arteries and inflammatory tissue damage in arterial and lung disease models, enabling doctors to provide effective treatment of life-threatening diseases.
- Sector
- Healthcare
- HQ
- Greenville, SC, United States
- Founded
- 2017
- Employees
- 6
- Website
- elastrin.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.